AI-assisted analysis based on the official CRS summary. Source version: Jul 30, 2026. Analysis updated: Sep 15, 2026.
01 — The Text
What.
- This act reauthorizes and revises federal programs addressing substance use disorders, overdoses, and mental health through fiscal year 2030.
- The bill extends funding for CDC prevention programs including prenatal substance use, drug-related infections, and overdose monitoring; expands grants for opioid overdose reversal drugs to first responders; and reestablishes HHS activities on fetal alcohol spectrum disorders.
- The act reauthorizes SAMHSA treatment and recovery programs including residential treatment for pregnant and postpartum women, peer-run training centers, and opioid recovery centers.
- New provisions authorize drug checking technologies (such as fentanyl test strips) through State and Tribal Opioid Response Grants; require HHS guidance on safe drug disposal; and establish cybersecurity protections for the 988 Suicide & Crisis Lifeline.
- The bill modifies pharmacy delivery rules for certain controlled substances and expands organizations that may provide DEA practitioner training.
02 — The Stakes
So what?
- Multiple prevention, treatment, and recovery programs receive statutory reauthorization and funding certainty through 2030, though the official summary does not specify appropriation amounts.
- The expansion of overdose reversal drug grants beyond FDA-approved opioids to legally marketed drugs for other substances broadens potential emergency response capacity, though effectiveness is not documented.
- New flexibility for State and Tribal Opioid Response Grants to fund drug checking technologies and expanded workforce development programs are authorized, but actual utilization and outcomes depend on state implementation and funding availability.
- Provisions requiring HHS studies and reports (on opioid analgesics, first episode psychosis funding, electronic health records, and grant awareness) establish oversight mechanisms, but findings and resulting policy changes are not yet documented.
- The official summary does not specify which programs receive increased funding, which receive decreased funding, or identify documented winners, losers, or quantified effects.
03 — The Path
Now what?
- The bill was signed by the President on December 1, 2025, and became Public Law No. 119-44.
- The Senate passed the bill without amendment by unanimous consent on September 18, 2025.
- HHS must implement specified actions including publishing guidance on drug disposal systems, updating references to opioid overdose reversal drugs in existing regulations and guidance within one year, and conducting required studies and convening public meetings.
- DEA will review HHS requests regarding scheduling of buprenorphine-naloxone combination products, though the official summary does not indicate a scheduled timeline for DEA review or decision.
Legislative History
Actions.
- Dec 1, 2025 — Became Public Law No: 119-44.
- Dec 1, 2025 — Became Public Law No: 119-44
- Dec 1, 2025 — Signed by President.
- Dec 1, 2025 — Signed by President.
- Nov 25, 2025 — Presented to President.
- Nov 25, 2025 — Presented to President.
- Sep 19, 2025 — Message on Senate action sent to the House.
- Sep 18, 2025 — Passed Senate without amendment by Unanimous Consent. (consideration: CR S6712)